In the high-stakes world of clinical trials, where a company’s multimillion-dollar drug development investment is at risk, the increasing complexity of these trials only compounds the challenges. Therefore, the development of a robust risk mitigation strategy, as a crucial component of comprehensive risk planning, is not just important but essential for effective drug development, particularly in the RBQM ecosystem. This emphasis on the urgency and significance of risk mitigation strategy can help the audience understand the gravity of the topic.

The paper introduces a novel framework for deriving an efficient risk mitigation strategy at the planning stage of a clinical trial and establishing operational rules (thresholds). This approach combines optimization and simulation models, offering a fresh perspective on risk management in clinical trials. The optimization model aims to derive an efficient contingency budget and allocate limited mitigation resources across mitigated risks. The simulation model aims to efficiently position the QTL/KRI and Secondary Limit thresholds for each risk to be aligned with risk assessment and contingency resources.

A compelling case study vividly illustrates the practical application and effectiveness of the proposed technique. This real-world example not only demonstrates the framework’s potential but also instills confidence in its successful implementation, reassuring the audience of its practicality and effectiveness.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data is random to illustrate the technique